Influence of Piribedil (Clarium®) on Vigilance and Cognitive Function in Patients With Parkinson's Disease Compared to Other Non-Ergot Dopamine Agonists

• Status: Completed
• Trial end date: 2011-12-01

Summary

The purpose of this clinical trial is to investigate the effects of the non-ergot dopamine agonist piribedil on vigilance and cognitive performances in patients with Parkinson's disease in comparison with other oral non-ergot dopamine agonists.

It should be tested whether piribedil is superior to continued pramipexole or ropinirole treatment regarding improvement of reduced vigilance and cognitive performance in patients with Parkinson's disease.

• Phase: Phase 3

Details

• Lead Sponsor: Desitin Arzneimittel GmbH
• Collaborator: FGK Clinical Research GmbH
• Treatments: Dopamine; Dopamine Agents; Dopamine Agonists; Loratadine; Piribedil; Pramipexole; Ropinirole